FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
|Videos|December 23, 2015
Overcoming Specialty Pharmacy Reporting Demands
Author(s)Davy James, Managing Editor
Joseph Morse, president and chief operating officer of Therigy, LLC, discusses how specialty pharmacies can meet the reporting requirements required by manufacturers and payers.
Advertisement
Joseph Morse, president and chief operating officer of Therigy, LLC, discusses how specialty pharmacies can meet the reporting requirements required by manufacturers and payers.
Advertisement
Related to this article
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5